Related Experiment Video

Updated: Aug 14, 2026

A Conditioned Place Preference Protocol for Measuring Incubation of Craving in Rats
04:11

A Conditioned Place Preference Protocol for Measuring Incubation of Craving in Rats

Published on: November 6, 2018

Activation of the spinal ERK signaling pathway contributes naloxone-precipitated withdrawal in morphine-dependent

Jun-Li Cao1, Jian-Hua He, Hai-Lei Ding

  • 1Department of Anesthesiology, Affiliated Hospital of Xuzhou Medical College, 99 Huaihai West Road, Xuzhou 221002, People's Republic of China Jiangsu Key Laboratory of Anesthesiology, Jiangsu Institute of Anesthesiology, 99 Huaihai West Road, Xuzhou 221002, People's Republic of China Department of Physiology, University of Texas, Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd, Dallas, TX 75390-9040, USA.

Pain
|November 18, 2005
PubMed

Insights

Spinal extracellular signal-regulated kinase (ERK) activation is crucial for morphine withdrawal symptoms. Inhibiting spinal ERK reduces withdrawal severity and associated pain, suggesting it as a therapeutic target for opioid dependence.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Molecular Biology

Background:

  • Extracellular signal-regulated kinase (ERK), a key mitogen-activated protein kinase (MAPK), mediates cellular responses to external stimuli.
  • Previous research indicates supraspinal ERK activation plays a role in drug dependence, particularly psychological aspects.
  • The role of spinal ERK in morphine withdrawal remains less understood.

Purpose of the Study:

  • To investigate the involvement of the spinal ERK signaling pathway in morphine withdrawal.
  • To determine if inhibiting spinal ERK can alleviate morphine withdrawal symptoms and associated pain.

Main Methods:

  • Chronic morphine administration in rats followed by naloxone-precipitated withdrawal.
  • Assessment of spinal ERK phosphorylation levels using Western blotting.
  • Intrathecal administration of a MEK inhibitor (U0126) or ERK antisense oligonucleotides to inhibit spinal ERK.
  • Evaluation of withdrawal scores, allodynia, and downstream targets like CREB and Fos expression.

Main Results:

  • Chronic morphine injection activated spinal ERK, with further increases during naloxone-precipitated withdrawal.
  • Inhibition or knockdown of spinal ERK significantly reduced morphine withdrawal scores and attenuated withdrawal-induced allodynia.
  • Spinal ERK inhibition decreased phosphorylation of downstream targets CREB and Fos expression.

Conclusions:

  • Activation of the spinal ERK signaling pathway is a critical component of naloxone-precipitated morphine withdrawal.
  • Targeting spinal ERK phosphorylation offers a potential therapeutic strategy for managing opioid withdrawal symptoms and associated hyperalgesia.

More Related Videos

Combining Laser Capture Microdissection and Microfluidic qPCR to Analyze Transcriptional Profiles of Single Cells: A Systems Biology Approach to Opioid Dependence09:54

Combining Laser Capture Microdissection and Microfluidic qPCR to Analyze Transcriptional Profiles of Single Cells: A Systems Biology Approach to Opioid Dependence

Published on: March 8, 2020

Assessment of Morphine-induced Hyperalgesia and Analgesic Tolerance in Mice Using Thermal and Mechanical Nociceptive Modalities07:23

Assessment of Morphine-induced Hyperalgesia and Analgesic Tolerance in Mice Using Thermal and Mechanical Nociceptive Modalities

Published on: July 29, 2014

Related Concept Videos

Opioid Receptors: Overview01:22

Opioid Receptors: Overview

Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2, D-Pen5]-enkephalin or DPDPE for...
Analgesia and Pain Management01:25

Analgesia and Pain Management

Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
Opioid Analgesics: Synthetic and Semisynthetic Opioids01:15

Opioid Analgesics: Synthetic and Semisynthetic Opioids

Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
Opioid Analgesics: Morphine and Other Natural Cogeners01:20

Opioid Analgesics: Morphine and Other Natural Cogeners

Opioids are a class of drugs that mimic endogenous opioid peptides and act on opioid receptors, and help in pain relief. These compounds are classified as natural, synthetic, or semi-synthetic. Natural opioids, like morphine, codeine, and thebaine, are derived from the opium poppy plant (Papaver somniferum or Papaver album) and are termed opiates. Synthetic opioids are artificial, while semi-synthetic opioids combine natural and synthetic compounds. Morphine, a prototypical opioid, possesses a...